Changes in Cerebrospinal Fluid, Liver and Intima-media-thickness Biomarkers in Patients with HIV-associated Neurocognitive Disorders Randomized to a Less Neurotoxic Treatment Regimen

Dementias Among Older Males and Females in the U.S. Medicare System With and Without HIV

(2023) Xiaoying Yu et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Correlations between cerebrospinal fluid biomarkers, neurocognitive tests, and resting-state electroencephalography (rsEEG) in patients with HIV-associated neurocognitive disorders

(2022) A. Barco et al.   JOURNAL OF NEUROVIROLOGY

Patterns of Cerebrospinal Fluid Alzheimer’s Dementia Biomarkers in People Living with HIV: Cross-Sectional Study on Associated Factors According to Viral Control, Neurological Confounders and Neurocognition

(2022) Mattia Trunfio et al.   Viruses-Basel

Impact of HIV-associated cognitive impairment on functional independence, frailty and quality of life in the modern era: a meta-analysis

(2022) Martins Nweke et al.   Scientific Reports

Quality of life in people living with HIV-associated neurocognitive disorder: A scoping review study

(2021) Kate Alford et al.   PLoS One

HIV and risk of dementia in older veterans

(2020) Kirsten Bobrow et al.   AIDS

Dual antiretroviral therapies are effective and safe regimens in the central nervous system of neurologically symptomatic people living with HIV

(2020) Mattia Trunfio et al.   AIDS

A review of the potential mechanisms of neuronal toxicity associated with antiretroviral drugs

(2020) Ilaria De Benedetto et al.   JOURNAL OF NEUROVIROLOGY

Protocol for a phase IV, open-label feasibility study investigating non-invasive markers of hepatic fibrosis in people living with HIV-1 and non-alcoholic fatty liver disease randomised to receiving optimised background therapy (OBT) plus maraviroc or OBT alone

(2020) Daniel Bradshaw et al.   BMJ Open

Comparison of dementia risk after age 50 between individuals with and without HIV infection

(2020) Jennifer O. Lam et al.   AIDS

Maraviroc intensification modulates atherosclerotic progression in HIV suppressed patients at high cardiovascular risk. A randomized, cross-over, pilot study

(2019) Daniela Francisci et al.   Open Forum Infectious Diseases

Plasma and CSF neurofilament light

(2019) Michelle M. Mielke et al.   NEUROLOGY

HIV-Associated Neurocognitive Impairment in the Modern ART Era: Are We Close to Discovering Reliable Biomarkers in the Setting of Virological Suppression?

(2019) Alessandra Bandera et al.   Frontiers in Aging Neuroscience

The effect of HIV infection, antiretroviral therapy on carotid intima-media thickness: A systematic review and meta-analysis

(2019) Titus F. Msoka et al.   LIFE SCIENCES

How helpful are the European AIDS Clinical Society cognitive screening questions in predicting cognitive impairment in an aging, well‐treated HIV‐positive population?

(2019) M Metral et al.   HIV MEDICINE

Diagnostic accuracy of new and old cognitive screening tools for HIV-associated neurocognitive disorders

(2018) M Trunfio et al.   HIV MEDICINE

Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: results of the neurocognitive substudy of the SALT randomized clinical trial

(2018) Ignacio Pérez-Valero et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

CNS-Targeted Antiretroviral Strategies: When Are They Needed and What to Choose

(2018) Andrea Calcagno et al.   Current HIV/AIDS Reports

Neurofilament light chain in blood is negatively associated with neuropsychological performance in HIV-infected adults and declines with initiation of antiretroviral therapy

(2018) Albert M. Anderson et al.   JOURNAL OF NEUROVIROLOGY

CSF extracellular vesicles and neurofilament light protein as biomarkers of CNS injury in HIV-infected patients on antiretroviral therapy

(2018) Debjani Guha et al.   AIDS

Diagnostic accuracy of noninvasive markers of steatosis, NASH and liver fibrosis in HIV-monoinfected individuals at-risk of non-alcoholic fatty liver disease (NAFLD)

(2018) Maud Lemoine et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Paroxetine and fluconazole therapy for HIV-associated neurocognitive impairment: results from a double-blind, placebo-controlled trial

(2017) Ned Sacktor et al.   JOURNAL OF NEUROVIROLOGY

Macrophage functions in lean and obese adipose tissue

(2017) Dylan Thomas et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Maraviroc-intensified combined antiretroviral therapy improves cognition in virally suppressed HIV-associated neurocognitive disorder

(2016) Thomas M. Gates et al.   AIDS

Liver Fibrosis Linked to Cognitive Performance in HIV and Hepatitis C

(2016) Victor G. Valcour et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Persistent CSF but not plasma HIV RNA is associated with increased risk of new-onset moderate-to-severe depressive symptoms; a prospective cohort study

(2016) Edward R. Hammond et al.   JOURNAL OF NEUROVIROLOGY

A decreasing CD4/CD8 ratio over time and lower CSF-penetrating antiretroviral regimens are associated with a higher risk of neurocognitive deterioration, independently of viral replication

(2016) Matteo Vassallo et al.   JOURNAL OF NEUROVIROLOGY

CCR5 blockade for neuroinflammatory diseases — beyond control of HIV

(2016) Guillaume Martin-Blondel et al.   Nature Reviews Neurology

Increased Intrathecal Immune Activation in Virally Suppressed HIV-1 Infected Patients with Neurocognitive Impairment

(2016) Arvid Edén et al.   PLoS One

Maraviroc Reduces Arterial Stiffness in PI-Treated HIV-infected Patients

(2016) Stefania Piconi et al.   Scientific Reports

Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study

(2016) Magnus Gisslén et al.   EBioMedicine

Could antiretroviral neurotoxicity play a role in the pathogenesis of cognitive impairment in treated HIV disease?

(2015) Jonathan Underwood et al.   AIDS

Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study

(2015) A. Mondi et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Blood brain barrier impairment is associated with cerebrospinal fluid markers of neuronal damage in HIV-positive patients

(2015) A. Calcagno et al.   JOURNAL OF NEUROVIROLOGY

Tau Protein Modifications and Interactions: Their Role in Function and Dysfunction

(2014) Anna Mietelska-Porowska et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND)

(2014) Lishomwa C. Ndhlovu et al.   JOURNAL OF NEUROVIROLOGY

Controversies in HIV-associated neurocognitive disorders

(2014) Sam Nightingale et al.   LANCET NEUROLOGY

The effects of Maraviroc on liver fibrosis in HIV/HCV co-infected patients

(2014) Enrique Ortega Gonzalez et al.   Journal of the International AIDS Society

Liver fibrosis is associated with cognitive impairment in HIV-positive patients

(2014) Nicoletta Ciccarelli et al.   Journal of the International AIDS Society

Neuroprotective maraviroc monotherapy in simian immunodeficiency virus-infected macaques

(2013) Kathleen M. Kelly et al.   AIDS

Relevance of lipopolysaccharide levels in HIV-associated neurocognitive impairment: the Neuradapt study

(2013) Matteo Vassallo et al.   JOURNAL OF NEUROVIROLOGY

Abnormal Liver Stiffness Assessed Using Transient Elastography (Fibroscan®) in HIV-Infected Patients without HBV/HCV Coinfection Receiving Combined Antiretroviral Treatment

(2013) Sang Hoon Han et al.   PLoS One

Alterations in Cerebrospinal Fluid Chemokines Are Associated With Maraviroc Exposure and In Vivo Metabolites Measurable by Magnetic Resonance Spectroscopy

(2012) Jaime H. Vera et al.   HIV CLINICAL TRIALS

Antiretroviral neurotoxicity

(2012) Kevin Robertson et al.   JOURNAL OF NEUROVIROLOGY

CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study

(2011) L. Garvey et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients

(2011) N. Ciccarelli et al.   NEUROLOGY

Treatment Intensification Has no Effect on the HIV-1 Central Nervous System Infection in Patients on Suppressive Antiretroviral Therapy

(2010) Aylin Yilmaz et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Serum Levels of the Immune Activation Marker Neopterin Change With Age and Gender and Are Modified by Race, BMI, and Percentage of Body Fat

(2010) M. E. Spencer et al.   JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES